Burgdorf – The Board of Directors of Ypsomed (SIX: YPSN) decided in its meeting on Monday, 13 June 2022, to carry out a capital increase from authorised capital created by the resolution of the Annual General Meeting on Wednesday, 30 June 2021, in the amount of a maximum of 1 million fully paid registered shares with a nominal value of CHF 14.15 each. The new shares will be offered to the existing shareholders at market conditions with a discount expected to be between 2% to 3%, while maintaining the subscription rights. It is envisaged to sell the unsubscribed shares in a free placement. There will be no trading of subscription rights. The new shares will be eligible for the dividend payment of 06 July 2022. Zürcher Kantonalbank is the Sole Global Coordinator of this capital increase.
Rights offering and free placement
Shareholders will be allocated one subscription right per registered share. The cut-off date for the allocation of rights is Wednesday, 15 June 2022, after close of trading. 13 subscription rights entitle the holder to purchase one offered share at the subscription or placement price, which will be determined at market conditions with a discount expected to be between 2% to 3%. The subscription and placement period lasts from Thursday, 16 June 2022, to Thursday, 23 June 2022, 12:00 noon CEST. Subscription rights that are not exercised will expire without compensation after the subscription period and will be available to the Board of Directors for free use in the interest of the Company. The definitive number of new shares and the definitive subscription or placement price are expected to be announced on Friday, 24 June 2022, based on the outcome of the subscription offer and the free placement. The first trading day of the new shares is scheduled for Tuesday, 28 June 2022.
Use of proceeds and actions of the majority shareholder
The funds accruing from the capital increase support the financing of the pre-investments in the accelerated production scale-up for injection systems and increase financial flexibility to drive digitization forward.
CEO Simon Michel is convinced of Ypsomed future prospects and underlines:
The long-term, demographic fundamentals and trends for our recurring business model are positive. The growth drivers’ selfcare of chronic diseases, the newest generation of liquid drug formulations, the expansion of global access to medicines as well as the opportunities for improved therapy management through digitalization all confirm that we are in the right track.
Major shareholder Dr. h.c. Willy Michel has already announced that he will exercise his subscription rights in full. It is planned to conduct the capital increase partially by conversion of the existing loans from Dr. h.c. Willy Michel (offset of claims) and partially by a contribution in cash.
Availability of prospectus
The prospectus is available free of charge from Zürcher Kantonalbank, IHKT, P.O. Box, 8010 Zurich (e-mail: email@example.com; phone +41 44 292 20 66).
Key data of the capital increase
|SIX Swiss Exchange
|Swiss security number share
|ISIN subscription right
|Swiss security number subscription right
|Subscription and placement price
|At market conditions with a discount expected to be between 2% to 3%
|13 : 1
|Number of new shares
|Maximum of 1'000'000 shares
|Number of shares after capital increase
|Maximum of 13'649'739 shares
|15 June 2022, after the close of trading
|Ex-date and start of rights exercise and placement period
|16 June 2022
|End of rights exercise and placement period
|23 June 2022, 12:00 noon CEST
|Publication of final subscription or placement price and definitive number of shares
|24 June 2022, before 07:30 am CEST
|First trading day and settlement
|28 June 2022
This media release and the information contained therein are not being issued in the United States of America, the United Kingdom or the European Economic Area and must not be distributed within or to such countries or via publications with a general circulation in such countries.
This media release serves informational purposes and constitutes neither an offer to sell nor a solicitation to buy any shares of YPSOMED HOLDING AG in any jurisdiction. This media release does not constitute a prospectus within the meaning of Article 35 et seqq. of the Swiss Federal Act on Financial Services. Investors should base their decision to purchase shares of YPSOMED HOLDING AG exclusively on the official prospectus. The shares described in the prospectus are publicly offered in Switzerland only. This media release is intended for the territory of Switzerland only. In addition, investors should seek advice from their bank or their financial adviser.
The information in this media release contains forward-looking statements and outlooks. Forward-looking statements and outlooks involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of YPSOMED HOLDING AG (including group companies), or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements and outlooks. Given these risks, uncertainties and other factors, recipients of this media release are cautioned not to place undue reliance on these forward-looking statements and outlooks. YPSOMED HOLDING AG (including group companies), does not have any obligation to update these forward-looking statements and outlooks to reflect future events or developments. Past performance or any prediction or forecast is not necessarily indicative of future performance. No assurance is given that any objectives, targets, or predictions will be met. The information in this media release does not constitute investment advice or recommendation and was prepared without regard to the specific objectives, financial situation or needs of any particular person who may receive it.
In addition, certain information provided in this media release qualifies as advertisement within the meaning of Article 68 FinSA. Investment decisions should only be made after a thorough reading of the prospectus and/or prospectus supplement, and, if necessary, after obtaining advice from a financial, legal and tax advisor regarding the risks and rewards of an investment. The documents mentioned can be obtained free of charge from Zürcher Kantonalbank (e-mail: firstname.lastname@example.org; phone: +41 44 292 20 66).